Belite Bio, Inc

Belite Bio, Inc (BLTE) priced its initial public offering on Apr 29, 2022 at $6.00 per ADS, raising $36M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $144.6M. Benchmark was lead-left underwriter. O’Melveny & Myers and Maples and Calder advised the company and Ellenoff Grossman & Schole advised the underwriters.

Belite Bio, Inc is a clinical-stage drug development company targeting retinal degeneration, including dry age-related macular degeneration and Stargardt disease, and metabolic diseases. Its lead candidate is LBS-008 (tinlarebant).

Status

IPO

Ticker

BLTE

Exchange

Nasdaq Capital Market

Priced

Apr 29, 2022

IPO price

$6.00 per ADS

Raised

$36M

Market cap at IPO price

$144.6M

First filed

Apr 5, 2022

Underwriters

Benchmark

Company counsel

O’Melveny & Myers and Maples and Calder

Underwriters' counsel

Ellenoff Grossman & Schole

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.